Judge: Pfizer ($PFE) ran afoul of competition law

A federal judge has ruled that Pfizer ($PFE) violated the California Unfair Competition Law by illegally promoting the Neurontin epilepsy drug. The finding stems from the same case in which a federal jury last March decided the drugmaker violated federal racketeering law for the same practices and must pay $142 million in damages. Report

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.